Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: seminole who wrote (1086)	8/13/1998 9:05:00 AM
From: Russian Bear	Read Replies (1) \| Respond to of 1826

All: On the Yahoo! MOGN message board, there is a very interesting synopsis of a European journal article detailing 114 vs. Taxol results, to date. Posts number 380 and 381. post.messages.yahoo.com@m2.yahoo.com RB

To: seminole who wrote (1086)	8/13/1998 12:40:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 1826

Efficacy of MGI-114 (6-Hydroxymethyacylfulvene, HMAF) Against the mdr/gp170 Metastatic MV522 Lung Carcinoma Xenograft by M.J. Kelner, T.C. Morris, L. Estes, K.M. Samson, R.D. Bagnell and R. Taetle Is this our very own Richard Dean Bagnell? Peter

To: seminole who wrote (1086)	8/14/1998 4:46:00 PM
From: David Cathcart	Read Replies (2) \| Respond to of 1826

Richard, I'm back, weary from 15 days business travel and looking forward to a family vacation at Litchfield Beach in South Carolina in two weeks. Congratulations on the recognition you are getting on the MOGN threads. Justly deserved! Now let's hope that humans are acting like mice in phase II. Your Florida State football team is a close second to Ohio State in the polls and is on the threshold of being number one. Let's hope that MGI 114 is also on the threshold of being top ranked in the world of cancer therapies. David